Vestmark Advisory Solutions Inc. Purchases 1,231 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Vestmark Advisory Solutions Inc. boosted its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 7.3% during the 4th quarter, Holdings Channel.com reports. The fund owned 18,120 shares of the medical research company’s stock after buying an additional 1,231 shares during the quarter. Vestmark Advisory Solutions Inc.’s holdings in Charles River Laboratories International were worth $4,284,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. abrdn plc raised its position in shares of Charles River Laboratories International by 872.0% in the 4th quarter. abrdn plc now owns 121,807 shares of the medical research company’s stock valued at $28,795,000 after acquiring an additional 109,275 shares during the period. Regency Capital Management Inc. DE acquired a new stake in shares of Charles River Laboratories International in the 4th quarter valued at approximately $3,703,000. WCM Investment Management LLC acquired a new stake in shares of Charles River Laboratories International in the 4th quarter valued at approximately $1,396,000. DekaBank Deutsche Girozentrale raised its position in shares of Charles River Laboratories International by 98.6% in the 4th quarter. DekaBank Deutsche Girozentrale now owns 14,094 shares of the medical research company’s stock valued at $3,333,000 after acquiring an additional 6,997 shares during the period. Finally, AMG National Trust Bank acquired a new stake in shares of Charles River Laboratories International in the 3rd quarter valued at approximately $1,119,000. Institutional investors own 98.91% of the company’s stock.

Insider Activity

In other news, EVP Shannon M. Parisotto sold 5,882 shares of the stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $241.20, for a total value of $1,418,738.40. Following the completion of the sale, the executive vice president now owns 2,596 shares of the company’s stock, valued at approximately $626,155.20. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other news, EVP Shannon M. Parisotto sold 5,882 shares of the stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $241.20, for a total value of $1,418,738.40. Following the completion of the sale, the executive vice president now owns 2,596 shares of the company’s stock, valued at approximately $626,155.20. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, VP William D. Barbo sold 4,050 shares of the firm’s stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $248.50, for a total value of $1,006,425.00. Following the sale, the vice president now directly owns 22,879 shares of the company’s stock, valued at approximately $5,685,431.50. The disclosure for this sale can be found here. In the last 90 days, insiders sold 14,932 shares of company stock valued at $3,693,663. 1.30% of the stock is owned by insiders.

Wall Street Analyst Weigh In

CRL has been the topic of a number of analyst reports. JPMorgan Chase & Co. increased their price target on shares of Charles River Laboratories International from $270.00 to $280.00 and gave the company an “overweight” rating in a research report on Thursday, February 15th. Citigroup increased their price target on shares of Charles River Laboratories International from $215.00 to $250.00 and gave the company a “neutral” rating in a research report on Thursday, February 15th. TheStreet raised Charles River Laboratories International from a “c+” rating to a “b-” rating in a research note on Friday, March 1st. Argus increased their target price on Charles River Laboratories International from $240.00 to $290.00 and gave the stock a “buy” rating in a research note on Monday, March 18th. Finally, Guggenheim cut Charles River Laboratories International from a “buy” rating to a “neutral” rating in a research note on Thursday, February 15th. Five research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $253.23.

Charles River Laboratories International Stock Up 1.6 %

Shares of CRL traded up $3.58 during mid-day trading on Friday, hitting $233.47. 466,193 shares of the company’s stock were exchanged, compared to its average volume of 482,082. The company has a market cap of $12.03 billion, a PE ratio of 25.35, a P/E/G ratio of 1.80 and a beta of 1.44. Charles River Laboratories International, Inc. has a 52 week low of $161.65 and a 52 week high of $275.00. The company has a 50-day simple moving average of $252.23 and a 200 day simple moving average of $223.97. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.52 and a quick ratio of 1.16.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.46 earnings per share for the quarter, topping the consensus estimate of $2.39 by $0.07. The company had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $991.25 million. Charles River Laboratories International had a net margin of 11.49% and a return on equity of 16.53%. The business’s quarterly revenue was down 7.9% on a year-over-year basis. During the same period last year, the business earned $2.98 EPS. On average, research analysts forecast that Charles River Laboratories International, Inc. will post 11.01 earnings per share for the current fiscal year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).